The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG)

A critical analysis from the perspective of the stakeholders at the end of the 17th legislative period

Nonfiction, Health & Well Being, Health
Cover of the book The early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products (AMNOG) by Sara Schlenkrich, GRIN Verlag
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Sara Schlenkrich ISBN: 9783656766018
Publisher: GRIN Verlag Publication: October 10, 2014
Imprint: GRIN Verlag Language: English
Author: Sara Schlenkrich
ISBN: 9783656766018
Publisher: GRIN Verlag
Publication: October 10, 2014
Imprint: GRIN Verlag
Language: English

Bachelor Thesis from the year 2013 in the subject Health Science, grade: 1,4, Neisse University Görlitz, course: V282129, language: English, abstract: The Act on the Reform of the Market for Medicinal Products, which entered into force on the 1st of January 2011, brought about a fundamental change in the balance of power on the pharmaceutical market. This thesis therefore sets out to answer the following question: What impact does the early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products have on the stakeholders of the healthcare system? To answer this question, this work first presents the theoretical foundations of the law, of the early benefit assessment and the bodies involved. It then takes stock of the decisions taken to date before describing the impact on the selected stakeholders. The following findings were reached: As the representative of the statutory health insurance funds, the Central Federal Association of Statutory Health Insurance Funds has gained in power and now decides, as a member of the Federal Joint Committee, on the added benefit of a drug and, depending on this decision, also on the future reimbursement rate. Pharmaceutical companies, however, are losing clout and must comply with the guidelines and assessments of the early benefit assessment. Patients stand to gain and lose out from the early benefit assessment. They are the ones who are ultimately dependent on the medicinal product and its improvement and benefit from a proven benefit. However, they have no say in the early benefit assessment procedure.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Bachelor Thesis from the year 2013 in the subject Health Science, grade: 1,4, Neisse University Görlitz, course: V282129, language: English, abstract: The Act on the Reform of the Market for Medicinal Products, which entered into force on the 1st of January 2011, brought about a fundamental change in the balance of power on the pharmaceutical market. This thesis therefore sets out to answer the following question: What impact does the early benefit assessment in the context of the Act on the Reform of the Market for Medicinal Products have on the stakeholders of the healthcare system? To answer this question, this work first presents the theoretical foundations of the law, of the early benefit assessment and the bodies involved. It then takes stock of the decisions taken to date before describing the impact on the selected stakeholders. The following findings were reached: As the representative of the statutory health insurance funds, the Central Federal Association of Statutory Health Insurance Funds has gained in power and now decides, as a member of the Federal Joint Committee, on the added benefit of a drug and, depending on this decision, also on the future reimbursement rate. Pharmaceutical companies, however, are losing clout and must comply with the guidelines and assessments of the early benefit assessment. Patients stand to gain and lose out from the early benefit assessment. They are the ones who are ultimately dependent on the medicinal product and its improvement and benefit from a proven benefit. However, they have no say in the early benefit assessment procedure.

More books from GRIN Verlag

Cover of the book Interessenorganisation Amnesty International. Welche Machtmittel hat Amnesty International in der Hand, um ihre speziellen Interessen in der BRD durchzusetzen? by Sara Schlenkrich
Cover of the book Effekte des Emissionshandels auf die Finanzmärkte - Chancen, Risiken, Produktinnovationen by Sara Schlenkrich
Cover of the book Gemeinwesenarbeit - Definitionen, Formen, Ziele by Sara Schlenkrich
Cover of the book Das Napoleonische System - Kennzeichen der französischen Hegemonie in Europa by Sara Schlenkrich
Cover of the book Vom ideellen Verein zum gewinnorientierten Unternehmen. Die professionelle Steuerung eines Fußballclubs by Sara Schlenkrich
Cover of the book Besonderheiten des Jahresabschlusses von Fußballvereinen by Sara Schlenkrich
Cover of the book Prozessoptimierung in der Beschaffung by Sara Schlenkrich
Cover of the book Data Warehouse by Sara Schlenkrich
Cover of the book Gender-Stereotyping in Children's Literature. A Case Study on the children's novel 'Matilda' by Roald Dahl by Sara Schlenkrich
Cover of the book Freiarbeit mit den sonderpädagogischen Schwerpunkten 'Geistige Entwicklung' und 'Autistische Behinderung' by Sara Schlenkrich
Cover of the book Mediennutzung von älteren Menschen und Reaktionen der Medienindustrie by Sara Schlenkrich
Cover of the book Der Konflikt in Darfur by Sara Schlenkrich
Cover of the book Zur Spieltheorie by Sara Schlenkrich
Cover of the book Der Gruppenprozess in der Klasse by Sara Schlenkrich
Cover of the book Case Management in der ambulanten Palliative Care by Sara Schlenkrich
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy